New Oral Kinase Inhibitor Axitinib Approved for Advanced Renal Cancer Pharmacy Practice News The FDA has approved the oral kinase inhibitor axitinib (Inlyta, Pfizer) for treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy, according to press releases from the FDA and Pfizer. FDA clears drug for advanced kidney cancer The Korea Herald FDA Grants Approval to Axitinib for the Treatment of Advanced Renal Cell Carcinoma Cancer Network FDA OKs Pfizer's Inlyta and accepts NDA for bosutinib The Pharma Letter TopNews New Zealand  - MedReps (subscription)  - Genetic Engineering News all 7 news articles »

...